.jetcityimage/iStock Editorial through Getty Images Morgan Stanley has actually selected Eli Lilly (NYSE: LLY) as its leading biopharma pick for 2025 as well as rated an additional nine labels in the room as overweight. The expenditure bank said in a details that it continues to strongly believe “diabesity is set to end up being.